ARCUTIS BIOTHERAPEUTICS INC (ARQT) — insider trading
Health Care · NASDAQ
ARCUTIS BIOTHERAPEUTICS INC (ARQT) has 78 reported SEC Form 4 insider transactions in our data, including 25 open-market sales among the most recent 78 (latest 2026-09-16).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-09-16 | Matsuda Masaru | Officer (See Remarks) | Open-market sale | 3,674 | $25.00 | $91.9K | Form 4 |
| 2026-09-15 | Welgus Howard G. | Director | Option exercise / conversion (derivative) | 2,255 | — | $0 | Form 4 |
| 2026-09-15 | Welgus Howard G. | Director | Option exercise / conversion (derivative) | 1,019 | — | $0 | Form 4 |
| 2026-09-15 | Welgus Howard G. | Director | Option exercise / conversion (derivative) | 822 | — | $0 | Form 4 |
| 2026-09-15 | Welgus Howard G. | Director | Open-market sale | 4,730 | $24.18 | $114.4K | Form 4 |
| 2026-09-15 | Welgus Howard G. | Director | Option exercise / conversion | 2,255 | $8.63 | $19.5K | Form 4 |
| 2026-09-15 | Welgus Howard G. | Director | Option exercise / conversion | 1,019 | $7.51 | $7.7K | Form 4 |
| 2026-09-15 | Welgus Howard G. | Director | Option exercise / conversion | 822 | $6.52 | $5.4K | Form 4 |
| 2026-09-08 | Matsuda Masaru | Officer (See Remarks) | Open-market sale | 9,989 | $25.03 | $250.0K | Form 4 |
| 2026-08-27 | Curran Terrie | Director | Option exercise / conversion (derivative) | 27,052 | — | $0 | Form 4 |
| 2026-08-27 | Curran Terrie | Director | Option exercise / conversion (derivative) | 11,148 | — | $0 | Form 4 |
| 2026-08-27 | Curran Terrie | Director | Open-market sale | 27,052 | $25.03 | $677.1K | Form 4 |
| 2026-08-27 | Curran Terrie | Director | Option exercise / conversion | 27,052 | $8.63 | $233.5K | Form 4 |
| 2026-08-27 | Curran Terrie | Director | Open-market sale | 11,148 | $25.03 | $279.0K | Form 4 |
| 2026-08-27 | Curran Terrie | Director | Option exercise / conversion | 11,148 | $7.51 | $83.7K | Form 4 |
| 2026-08-20 | Curran Terrie | Director | Option exercise / conversion (derivative) | 1,072 | — | $0 | Form 4 |
| 2026-08-20 | Curran Terrie | Director | Open-market sale | 1,072 | $26.04 | $27.9K | Form 4 |
| 2026-08-20 | Curran Terrie | Director | Option exercise / conversion | 1,072 | $7.51 | $8.1K | Form 4 |
| 2026-08-19 | Burnett Patrick | Officer (See Remarks) | Open-market sale | 1,697 | $27.00 | $45.8K | Form 4 |
| 2026-08-17 | Welgus Howard G. | Director | Option exercise / conversion (derivative) | 2,255 | — | $0 | Form 4 |
| 2026-08-17 | Welgus Howard G. | Director | Option exercise / conversion (derivative) | 1,019 | — | $0 | Form 4 |
| 2026-08-17 | Welgus Howard G. | Director | Option exercise / conversion (derivative) | 822 | — | $0 | Form 4 |
| 2026-08-17 | Welgus Howard G. | Director | Open-market sale | 4,730 | $26.18 | $123.8K | Form 4 |
| 2026-08-17 | Welgus Howard G. | Director | Option exercise / conversion | 2,255 | $8.63 | $19.5K | Form 4 |
| 2026-08-17 | Welgus Howard G. | Director | Option exercise / conversion | 1,019 | $7.51 | $7.7K | Form 4 |
| 2026-08-17 | Welgus Howard G. | Director | Option exercise / conversion | 822 | $6.52 | $5.4K | Form 4 |
| 2026-08-12 | Burnett Patrick | Officer (See Remarks) | Option exercise / conversion (derivative) | 6,700 | — | $0 | Form 4 |
| 2026-08-12 | Burnett Patrick | Officer (See Remarks) | Open-market sale | 6,700 | $26.08 | $174.8K | Form 4 |
| 2026-08-12 | Burnett Patrick | Officer (See Remarks) | Option exercise / conversion | 6,700 | $3.64 | $24.4K | Form 4 |
| 2026-08-11 | Burnett Patrick | Officer (See Remarks) | Option exercise / conversion (derivative) | 8,300 | — | $0 | Form 4 |
| 2026-08-11 | Burnett Patrick | Officer (See Remarks) | Open-market sale | 8,300 | $26.52 | $220.1K | Form 4 |
| 2026-08-11 | Burnett Patrick | Officer (See Remarks) | Option exercise / conversion | 8,300 | $3.64 | $30.2K | Form 4 |
| 2026-08-03 | Watanabe Todd | Director, Officer (See Remarks) | Open-market sale | 4,375 | $26.12 | $114.3K | Form 4 |
| 2026-08-03 | Matsuda Masaru | Officer (See Remarks) | Open-market sale | 1,230 | $26.12 | $32.1K | Form 4 |
| 2026-08-03 | Burnett Patrick | Officer (See Remarks) | Open-market sale | 955 | $26.12 | $24.9K | Form 4 |
| 2026-07-15 | Welgus Howard G. | Director | Option exercise / conversion (derivative) | 2,255 | — | $0 | Form 4 |
| 2026-07-15 | Welgus Howard G. | Director | Option exercise / conversion (derivative) | 1,019 | — | $0 | Form 4 |
| 2026-07-15 | Welgus Howard G. | Director | Option exercise / conversion (derivative) | 822 | — | $0 | Form 4 |
| 2026-07-15 | Welgus Howard G. | Director | Open-market sale | 4,730 | $26.91 | $127.3K | Form 4 |
| 2026-07-15 | Welgus Howard G. | Director | Option exercise / conversion | 2,255 | $8.63 | $19.5K | Form 4 |
| 2026-07-15 | Welgus Howard G. | Director | Option exercise / conversion | 1,019 | $7.51 | $7.7K | Form 4 |
| 2026-07-15 | Welgus Howard G. | Director | Option exercise / conversion | 822 | $6.52 | $5.4K | Form 4 |
| 2026-07-15 | Peetz Christopher | Director | Grant / award / vesting (derivative) | 13,010 | — | $0 | Form 4 |
| 2026-07-15 | Peetz Christopher | Director | Grant / award / vesting (derivative) | 21,486 | — | $0 | Form 4 |
| 2026-07-15 | Peetz Christopher | Director | Grant / award / vesting | 4,315 | — | $0 | Form 4 |
| 2026-06-17 | Welgus Howard G. | Director | Open-market sale | 635 | $25.67 | $16.3K | Form 4 |
| 2026-06-15 | Welgus Howard G. | Director | Option exercise / conversion (derivative) | 2,255 | — | $0 | Form 4 |
| 2026-06-15 | Welgus Howard G. | Director | Option exercise / conversion (derivative) | 1,019 | — | $0 | Form 4 |
| 2026-06-15 | Welgus Howard G. | Director | Option exercise / conversion (derivative) | 822 | — | $0 | Form 4 |
| 2026-06-15 | Welgus Howard G. | Director | Open-market sale | 4,096 | $24.41 | $100.0K | Form 4 |
| 2026-06-15 | Welgus Howard G. | Director | Option exercise / conversion | 2,255 | $8.63 | $19.5K | Form 4 |
| 2026-06-15 | Welgus Howard G. | Director | Option exercise / conversion | 1,019 | $7.51 | $7.7K | Form 4 |
| 2026-06-15 | Welgus Howard G. | Director | Option exercise / conversion | 822 | $6.52 | $5.4K | Form 4 |
| 2026-06-15 | LIN SUE-JEAN | Director | Open-market sale | 4,946 | $24.38 | $120.6K | Form 4 |
| 2026-06-05 | Krishnamohan Neha | Director | Grant / award / vesting (derivative) | 16,667 | — | $0 | Form 4 |
| 2026-06-05 | Krishnamohan Neha | Director | Grant / award / vesting | 5,778 | — | $0 | Form 4 |
| 2026-06-05 | Gilbert Halley E | Director | Grant / award / vesting (derivative) | 16,667 | — | $0 | Form 4 |
| 2026-06-05 | Gilbert Halley E | Director | Grant / award / vesting | 5,778 | — | $0 | Form 4 |
| 2026-06-05 | Munshi Amit | Director | Grant / award / vesting (derivative) | 16,667 | — | $0 | Form 4 |
| 2026-06-05 | Munshi Amit | Director | Grant / award / vesting | 5,778 | — | $0 | Form 4 |
| 2026-06-05 | Curran Terrie | Director | Grant / award / vesting (derivative) | 16,667 | — | $0 | Form 4 |
| 2026-06-05 | Curran Terrie | Director | Grant / award / vesting | 5,778 | — | $0 | Form 4 |
| 2026-06-05 | Leonard Keith R | Director | Grant / award / vesting (derivative) | 16,667 | — | $0 | Form 4 |
| 2026-06-05 | Leonard Keith R | Director | Grant / award / vesting | 5,778 | — | $0 | Form 4 |
| 2026-06-05 | Welgus Howard G. | Director | Grant / award / vesting (derivative) | 16,667 | — | $0 | Form 4 |
| 2026-06-05 | Welgus Howard G. | Director | Grant / award / vesting | 5,778 | — | $0 | Form 4 |
| 2026-06-05 | LIN SUE-JEAN | Director | Grant / award / vesting (derivative) | 16,667 | — | $0 | Form 4 |
| 2026-06-05 | LIN SUE-JEAN | Director | Grant / award / vesting | 5,778 | — | $0 | Form 4 |
| 2026-06-05 | Heron Patrick J | Director | Grant / award / vesting (derivative) | 16,667 | — | $0 | Form 4 |
| 2026-06-05 | Heron Patrick J | Director | Grant / award / vesting | 5,778 | — | $0 | Form 4 |
| 2026-05-11 | Burnett Patrick | Officer (See Remarks) | Open-market sale | 222 | $21.05 | $4.7K | Form 4 |
| 2026-05-11 | Vairavan Latha | Officer (SVP Chief Financial Officer) | Open-market sale | 435 | $21.05 | $9.2K | Form 4 |
| 2026-05-04 | Watanabe Todd | Director, Officer (See Remarks) | Open-market sale | 3,172 | $23.61 | $74.9K | Form 4 |
| 2026-05-04 | Vairavan Latha | Officer (SVP Chief Financial Officer) | Open-market sale | 1,341 | $23.61 | $31.7K | Form 4 |
| 2026-05-04 | Burnett Patrick | Officer (See Remarks) | Open-market sale | 684 | $23.61 | $16.1K | Form 4 |
| 2026-05-04 | Matsuda Masaru | Officer (See Remarks) | Open-market sale | 884 | $23.61 | $20.9K | Form 4 |
| 2026-05-04 | Matsuda Masaru | Officer (See Remarks) | Open-market sale | 7,372 | $23.27 | $171.5K | Form 4 |
| 2026-05-01 | Welgus Howard G. | Director | Open-market sale | 7,144 | $22.99 | $164.2K | Form 4 |
Ask the chat about ARQT's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: ARCUTIS BIOTHERAPEUTICS INC (ARQT).
Last updated 2026-09-16 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.